Insmeds lung drug meets main goal in late-stage study

Insmed Inc said its drug for the treatment of a rare and serious lung disorder met the main goal in a late-stage study, sending its shares up 75 percent in premarket trading on Tuesday.

The company said the addition of the drug, Alis, to basic therapy showed statistical significance in reducing the lung disease by the sixth month in 29 percent of patients, compared with 9 percent in patients on basic treatment.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)